Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FLJ13224, also annotated as uncharacterized LOC79857, refers to an RNA gene or open reading frame that currently lacks experimental evidence for protein function, molecular classification, or relevance to disease. It is also listed as family with sequence similarity 60 member A (FAM60A) in some genomic databases[4]. No information is available to support its role as a receptor, enzyme, transporter, or any other characterized molecular target[1][4][7]. There are no data on involvement in signaling pathways, disease association, or druggability. The gene is labeled as "uncharacterized," meaning no definitive molecular function or involvement in biological pathways has been established in the literature[1][4][7]. There are no reports of drugs, biomarkers, safety concerns, or disease relevance related to this gene. The presence of the symbol "FLJ13224" and LOC number points to automated or high-throughput genome annotation rather than experimentally validated function. Some sources suggest the gene has been mapped or renamed as "family with sequence similarity 60 member A" (FAM60A), but no additional functional data are available[4]. Such uncharacterized entries are common in large-scale genome projects; detailed annotation is lacking until experimental validation or further bioinformatic analysis can provide functional insight[3][5]. In summary: FLJ13224/uncharacterized LOC79857 currently does not meet criteria for therapeutic target characterization, nor does it have established biological or clinical significance based on available data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 60 member A (FAM60A) (FAM60A).